Galmed Pharmaceuticals Ltd.

NasdaqCM:GLMD Stock Report

Market Cap: US$4.2m

Galmed Pharmaceuticals Valuation

Is GLMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GLMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GLMD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GLMD's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GLMD?

Key metric: As GLMD is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for GLMD. This is calculated by dividing GLMD's market cap by their current book value.
What is GLMD's PB Ratio?
PB Ratio0.2x
BookUS$18.44m
Market CapUS$4.22m

Price to Book Ratio vs Peers

How does GLMD's PB Ratio compare to its peers?

The above table shows the PB ratio for GLMD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.6x
APVO Aptevo Therapeutics
1.3x64.0%US$4.9m
WINT Windtree Therapeutics
1.3x-84.7%US$4.5m
DWTX Dogwood Therapeutics
3.6x-21.6%US$3.6m
FRTX Fresh Tracks Therapeutics
0.4xn/aUS$4.3m
GLMD Galmed Pharmaceuticals
0.2xn/aUS$4.2m

Price-To-Book vs Peers: GLMD is good value based on its Price-To-Book Ratio (0.2x) compared to the peer average (1.6x).

Price to Book Ratio vs Industry

How does GLMD's PB Ratio compare vs other companies in the US Biotechs Industry?

60 CompaniesPrice / BookEstimated GrowthMarket Cap
Industry Avg.1.9x28.4%
GLMD Galmed Pharmaceuticals
 0.2xn/aUS$4.22m
GRAL GRAIL
0.2x35.7%US$550.38m
IMAB I-Mab
0.4x1.8%US$78.16m
GLMD 0.2xIndustry Avg. 1.9xNo. of Companies82PB01.63.24.86.48+
60 CompaniesEstimated GrowthMarket Cap
Industry Avg.1.9x28.4%
GLMD Galmed Pharmaceuticals
 0.2xn/aUS$4.22m
No more companies

Price-To-Book vs Industry: GLMD is good value based on its Price-To-Book Ratio (0.2x) compared to the US Biotechs industry average (1.8x).

Price to Book Ratio vs Fair Ratio

What is GLMD's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GLMD PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate GLMD's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

IQVIA Holdings

US$35.9b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

7D

4.7%

1Y

-4.8%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$56.91

7D

0.6%

1Y

9.8%